Views: 0 Author: Site Editor Publish Time: 2026-11-16 Origin: Site
HKeyBio Industry Commentary
Top 5 Immune Mediated Gastrointestinal Diseases
Autoimmune Top 5 Series
Originally published in Chinese on April 21, 2026. Drug status and development context are presented as of that date.
HKeyBio’s take. Five gastrointestinal indications illustrate how immune dysregulation and mucosal injury create different development challenges. Crohn’s disease and ulcerative colitis have multiple approved therapies, yet durable disease control remains a priority. Eosinophilic disorders and celiac disease call for approaches tailored to the affected tissue and the mechanism driving injury.
These conditions can relapse, vary considerably between patients and leave substantial unmet needs. Crohn’s disease and ulcerative colitis are forms of inflammatory bowel disease (IBD). Eosinophilic esophagitis and eosinophilic gastroenteritis are immune-mediated eosinophilic disorders. Celiac disease is a gluten-triggered autoimmune enteropathy. The five conditions below keep the order of the Chinese article and represent distinct clinical and research priorities [1–7].
Table 1. Sites, pathology and clinical challenges across five immune-mediated gastrointestinal diseases. Prevalence varies by region, case definition and ascertainment [1,2,5–7].
02 Disease Features and Development Priorities
Crohn’s disease (CD) is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract, often including the terminal ileum. It commonly presents in young adulthood, including during the twenties. Th1- and Th17-associated responses contribute to its immunopathology. Transmural inflammation can lead to strictures, fistulas and other complications. Patients often need long-term maintenance treatment, and loss of response to biologics remains a challenge [1,8].
Table 2. Representative Crohn’s disease agents, mechanisms and U.S. indications as of April 21, 2026 [8–10,24].
R&D focus. Selective IL-23 p19 inhibitors and oral small molecules are major development directions. Gut-directed delivery and antifibrotic strategies aim to address exposure and fibrotic strictures. Cell-based approaches have also been explored, particularly for complex perianal fistulas. For example, the confirmatory darvadstrocel study did not meet its primary endpoint, and the product was withdrawn from the EU market [11].
Ulcerative colitis (UC) usually involves continuous inflammation of the colonic mucosa beginning in the rectum. Bloody, mucus-containing stools and recurrent diarrhea are common. Some patients with moderate to severe UC become steroid-dependent or have an inadequate response to corticosteroids. Colorectal cancer risk increases with longstanding colonic inflammation. Guidelines commonly use about eight years after symptom onset as the point for initial surveillance assessment, with timing adjusted to risk [2,12].
Table 3. Representative ulcerative colitis agents, mechanisms and U.S. indications as of April 21, 2026 [2,13,14].
R&D focus. Durable mucosal healing is a central objective. Gut-selective approaches aim to limit systemic exposure or effects while maintaining efficacy in the colon. Earlier inflammatory control and surveillance are also relevant to long-term neoplasia risk. Cancer risk reduction remains a question for long-term evaluation [2,12].
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by esophageal dysfunction and mucosal eosinophilia. It affects children as well as adults. Dysphagia and food impaction are characteristic in older children and adults, and symptoms may overlap with gastroesophageal reflux. Feeding difficulty in younger children can compromise growth [3].
Table 4. Eosinophilic esophagitis therapies and representative investigational evidence as of April 21, 2026 [15–17].
R&D focus. Treatment development aims to reduce mucosal eosinophilia, improve esophageal function and sustain control. Swallowed topical corticosteroids act locally, while biologics can target upstream type 2 signaling. Studies of dietary trigger avoidance alongside drug treatment can help clarify how to maintain remission. Histology, endoscopic findings and symptoms each contribute to assessing response [3,15–17].
Eosinophilic gastroenteritis (EGE) is a historical term for uncommon eosinophilic disorders involving the stomach and/or small bowel. Current consensus favors naming the affected segment, such as eosinophilic gastritis or eosinophilic enteritis. Mucosal, muscular and serosal patterns can present differently. Abdominal pain and diarrhea are common, muscular involvement can cause obstruction, and serosal disease can cause ascites. Nonspecific symptoms can delay diagnosis [4,5].
Table 5. Representative approaches to non-esophageal eosinophilic gastrointestinal disease. The two biologic examples were studied in eosinophilic gastritis [5,18,19].
R&D focus. Drug repurposing and type 2 pathway modulation are important directions in these uncommon conditions. Local gastrointestinal delivery could reduce exposure to systemic corticosteroids. Trials should assess symptoms and tissue response together. For example, a phase 2 benralizumab study showed histologic effects, while a clear symptomatic benefit was not established [18].
Celiac disease (CeD) is an autoimmune enteropathy triggered by dietary gluten in genetically predisposed individuals, usually those carrying HLA-DQ2 and/or HLA-DQ8. Small-intestinal villous atrophy can contribute to diarrhea, malabsorption and nutritional deficiencies. A strict lifelong gluten-free diet is the standard treatment. As of April 21, 2026, the FDA had approved no drug specifically for celiac disease [7,20].
Table 6. Investigational celiac disease approaches as of April 21, 2026. Examples represent published clinical studies [20–23].
R&D focus. Two priorities are to reduce exposure to immunogenic gluten peptides and to limit the intestinal immune response they trigger. Oral approaches include gluten-degrading enzymes and small molecules that reduce peptide immunogenicity upstream of antigen presentation. Targeted immune pathways, including IL-15, are also under study. The aim is to complement dietary management and address unresolved needs such as inadvertent exposure or refractory disease [20–23].
Table 7. Research priorities and development context as of April 21, 2026.
In CD and UC, a broad set of established therapies has shifted development toward greater selectivity, gut-directed effects, durable remission and mucosal healing. EoE now has approved targeted and swallowed topical options. EGE-related indications and CeD have different evidence bases, with ongoing interest in drug repurposing, pathway-specific therapies and endpoints that capture meaningful tissue and clinical benefit.
Local gastrointestinal delivery, more selective immune modulation and combinations of complementary mechanisms are priorities for further research. Their value will depend on the affected segment, the target and the outcomes a study needs to improve.
Author. Irene
Reviewed by Ding Ying
Edited by Jing Yan
Disclaimer. This article is for general information and offers no investment advice. Readers are responsible for decisions based on the article. HKeyBio makes no express or implied warranty as to the accuracy, reliability or completeness of this material. Please contact HKeyBio about any rights concerns so the material can be reviewed and removed where appropriate.
HKeyBio is a preclinical contract research organization specializing in in vivo efficacy studies for autoimmune diseases. Its core technical team has more than 20 years of autoimmune drug development experience. The company has ISO 9001 certification and operates molecular, cellular, pathology, small-animal and analytical facilities in Suzhou Industrial Park, alongside nonhuman primate study facilities in Suzhou and Guangxi. The original article reported approximately 60 employees and project leads with master’s or doctoral degrees. The team supports preclinical studies and investigational new drug (IND) submissions.
· 50+ nonhuman primate models of autoimmune disease
· 300+ animal models of autoimmune disease
[1] Chinese Society of Gastroenterology. Chinese guidelines for diagnosis and treatment of Crohn’s disease (2023, Guangzhou). Source
[2] Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline update on ulcerative colitis in adults. Am J Gastroenterol. 2025;120:1187–1224. Source
[3] Dellon ES, Muir AB, Katzka DA, et al. ACG clinical guideline on diagnosis and management of eosinophilic esophagitis. Am J Gastroenterol. 2025;120:31–59. Source
[4] Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20:2474–2484.e3. Source
[5] Li K, Ruan G, Liu S, et al. Eosinophilic gastroenteritis: Pathogenesis, diagnosis, and treatment. Chin Med J (Engl). 2023;136:899–909. Source
[6] Hahn JW, et al. Global incidence and prevalence of eosinophilic esophagitis, 1976–2022. Clin Gastroenterol Hepatol. 2023;21:3270–3284.e77. Source
[7] Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease. Clin Gastroenterol Hepatol. 2018;16:823–836.e2. Source
[8] Lichtenstein GR, Loftus EV Jr, Afzali A, et al. ACG clinical guideline on management of Crohn’s disease in adults. Am J Gastroenterol. 2025;120:1225–1264. Source
[9] US Food and Drug Administration. Rinvoq (upadacitinib) prescribing information. 2025. Source
[10] US Food and Drug Administration. Stelara (ustekinumab) prescribing information. 2025. Source
[11] European Medicines Agency. Direct healthcare professional communication on withdrawal of Alofisel (darvadstrocel) from the EU market. December 2024. Source
[12] European Crohn’s and Colitis Organisation. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023;17:827–854. Source
[13] US Food and Drug Administration. Omvoh (mirikizumab) prescribing information. 2025. Source
[14] US Food and Drug Administration. Xeljanz (tofacitinib) prescribing information. 2024. Source
[15] US Food and Drug Administration. Dupilumab approvals for eosinophilic esophagitis. Orphan Drug Designations and Approvals. Source
[16] US Food and Drug Administration. Eohilia (budesonide oral suspension) prescribing information. 2024. Source
[17] Dellon ES, Peterson KA, Mitlyng BL, et al. Mepolizumab for adolescents and adults with eosinophilic oesophagitis. Gut. 2023;72:1828–1837. Source
[18] Kliewer KL, Murray-Petzold C, Collins MH, et al. Benralizumab for eosinophilic gastritis: A phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:803–815. Source
[19] ClinicalTrials.gov. Dupilumab Eosinophilic Gastritis Study (DEGAS). NCT03678545. Source
[20] Doyle JB, Silvester J, Ludvigsson JF, Lebwohl B. Advances in the pathophysiology, diagnosis, and management of celiac disease. BMJ. 2025;391:e081353. Source
[21] Lähdeaho ML, Scheinin M, Vuotikka P, et al. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: A phase 2a trial. Lancet Gastroenterol Hepatol. 2019;4:948–959. Source
[22] Murray JA, Syage JA, Wu TT, et al. Latiglutenase in patients with celiac disease exposed to a gluten challenge. Source
[23] Schuppan D, Mäki M, Lundin KEA, et al. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. N Engl J Med. 2021;385:35–45. Source
[24] US Food and Drug Administration. Skyrizi (risankizumab) prescribing information. 2024. Source